Breaking News Instant updates and real-time market news.

QGEN

Qiagen

$35.41

0.16 (0.45%)

, NEO

NeoGenomics

$16.39

-0.23 (-1.38%)

16:10
11/30/18
11/30
16:10
11/30/18
16:10

Qiagen, NeoGenomics to accelerate diagnostics for medicine for cancer patients

Qiagen (QGEN) and NeoGenomics (NEO) announced a master service agreement to accelerate the availability of companion diagnostics that enable precision medicine for cancer patients. The partnership between Qiagen and NeoGenomics, a provider of cancer-focused genetic testing services, will ensure day-one patient access to FDA-approved molecular tests paired with newly approved drugs for cancer. Building on the FDA's modernized regulatory approach to advanced diagnostics, especially next-generation sequencing, or NGS, tests, the collaboration with NeoGenomics will allow Qiagen and pharmaceutical partners to streamline the development and launch of targeted drugs and companion diagnostics to guide treatment decisions. The partnership offers pathways leading to introduction of FDA-approved companion diagnostics simultaneously with launch of new therapies. Qiagen and NeoGenomics will discuss their efforts to expedite access for precision medicine solutions at the American Society of Hematology, or ASH.

QGEN

Qiagen

$35.41

0.16 (0.45%)

NEO

NeoGenomics

$16.39

-0.23 (-1.38%)

  • 30

    Nov

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

QGEN Qiagen
$35.41

0.16 (0.45%)

01/29/18
GSCO
01/29/18
INITIATION
Target $39
GSCO
Buy
Qiagen initiated with a Buy at Goldman Sachs
Goldman analyst Patrick Donnelly initiated Qiagen with a Buy and $39 price target telling investors it will benefit from a wave of diagnostics product cycles which should lead to MSD-HSD organic growth as HPV headwinds abate in first half 2018.
01/22/18
LEHM
01/22/18
NO CHANGE
Target $60
LEHM
Overweight
Quidel price target raised to $60 from $50 at Barclays
Barclays analyst Jack Meehan raised his price target for Quidel (QDEL) to $60 from $50 and for Qiagen (QGEN) to $40 from $39 ahead of the companies' Q4 results. The fundamental drivers for the Life Science Tools & Diagnostics group are "on a solid footing" into earnings, Meehan tells investors in a research note. The analyst favors both names with Overweight ratings.
01/08/18
PIPR
01/08/18
NO CHANGE
PIPR
Qiagen, DiaSorin partnership could be disruptive to TB market, says Piper Jaffray
Piper Jaffray analyst William Quirk notes that Qiagen (QGEN) announced a partnership with DiaSorin to develop an automated QuantiFERONTB test for the LIAISON analyzers, and argues that it could be disruptive to the existing physician office latent TB market. The analyst believes the agreement could put pressure on some of Oxford's (OXFD) business and potentially force the company to sign a similar deal with a different immunoassay provider. Quirk points out that Oxford also announced preliminary Q4 revenue below the Street, and while the company did not explain the weak results, he believes it was from U.S. immigration weakness and China order timing.
01/03/18
EVER
01/03/18
INITIATION
Target $35
EVER
Outperform
Qiagen initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ross Muken initiated Qiagen with an Outperform rating and $35 price target.
NEO NeoGenomics
$16.39

-0.23 (-1.38%)

11/01/18
BNCH
11/01/18
NO CHANGE
Target $22
BNCH
Buy
NeoGenomics price target raised to $22 from $16 at Benchmark
Benchmark analyst Bruce Jackson noted that NeoGenomics reported earnings and revenue that beat his estimates and the company raised its revenue and adjusted EPS expectations. After raising both his estimates for 2018 and 2019 and raising the multiple he applies, Jackson lifted his price target on NeoGenomics shares to $22 and keeps a Buy rating on the stock.
10/31/18
CHLM
10/31/18
NO CHANGE
Target $22
CHLM
Buy
NeoGenomics price target raised to $22 from $17 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for NeoGenomics to $22 from $17 given "excellent" Q3 results and as Genoptix acquisition adds another layer of growth. The analyst reiterates a Buy rating on the shares.
10/24/18
FANA
10/24/18
UPGRADE
Target $18
FANA
Strong Buy
NeoGenomics upgraded to Strong Buy from Outperform at First Analysis
First Analysis analyst Joseph Munda upgraded NeoGenomics to Strong Buy and raised his price target for the shares to $18 from $16. The analyst views the company's acquisition of clinical oncology testing leader Genoptix as a "major positive." The combined company should benefit from greater geographical coverage, a broader test menu, enhanced service capabilities, and deeper access to oncologists, Munda tells investors in a research note.
10/23/18
RAJA
10/23/18
INITIATION
Target $16
RAJA
Outperform
NeoGenomics resuming with an Outperform at Raymond James
Raymond James analyst John Hsu resumed coverage on NeoGenomics with an Outperform and $16 price target telling investors it is well positioned as a leading pure play oncology testing company.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
11/22/19
11/22
13:17
11/22/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
11/22/19
11/22
13:16
11/22/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKR

Baker Hughes

$22.59

(0.00%)

13:04
11/22/19
11/22
13:04
11/22/19
13:04
Hot Stocks
Baker Hughes reports U.S. rig count down 3 to 803 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOLD

Audentes Therapeutics

$28.17

0.05 (0.18%)

13:02
11/22/19
11/22
13:02
11/22/19
13:02
Recommendations
Audentes Therapeutics analyst commentary  »

Piper remains buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYNL

Synalloy

$13.45

(0.00%)

13:01
11/22/19
11/22
13:01
11/22/19
13:01
Hot Stocks
Synalloy board of directors decides not to make annual dividend payment »

Synalloy Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKR

Baker Hughes

$22.60

0.01 (0.04%)

13:01
11/22/19
11/22
13:01
11/22/19
13:01
Hot Stocks
Breaking Hot Stocks news story on Baker Hughes »

Baker Hughes reports U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$119.65

-0.23 (-0.19%)

12:53
11/22/19
11/22
12:53
11/22/19
12:53
Periodicals
Walmart's Jet.com to stop delivering fresh groceries, CNBC reports »

Walmart's Jet.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$30.99

-0.45 (-1.43%)

12:48
11/22/19
11/22
12:48
11/22/19
12:48
Recommendations
Skyline analyst commentary  »

SunTrust boosts Skyline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:47
11/22/19
11/22
12:47
11/22/19
12:47
Hot Stocks
Breaking Hot Stocks news story  »

Civista Bancshares…

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

12:46
11/22/19
11/22
12:46
11/22/19
12:46
Periodicals
Breaking Periodicals news story on We Company, SoftBank, SoftBank »

WeWork chairman lays out…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Z

Zillow

$41.03

1.22 (3.06%)

12:45
11/22/19
11/22
12:45
11/22/19
12:45
Options
Zillow call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
11/22/19
11/22
12:45
11/22/19
12:45
General news
Breaking General news story  »

Week of 11/22…

12:45
11/22/19
11/22
12:45
11/22/19
12:45
General news
Breaking General news story  »

Week of 11/22…

12:42
11/22/19
11/22
12:42
11/22/19
12:42
Hot Stocks
Breaking Hot Stocks news story  »

Civista Bancshares…

BIIB

Biogen

$294.17

5.51 (1.91%)

12:33
11/22/19
11/22
12:33
11/22/19
12:33
Periodicals
Breaking Periodicals news story on Biogen »

Biogen settles Tecfidera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

BIIB

Biogen

$293.68

5.02 (1.74%)

12:26
11/22/19
11/22
12:26
11/22/19
12:26
Hot Stocks
Breaking Hot Stocks news story on Biogen »

Biogen rallies 3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

FTCH

Farfetch

$9.73

0.335 (3.57%)

12:25
11/22/19
11/22
12:25
11/22/19
12:25
Options
Farfetch Limited call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$310.63

0.34 (0.11%)

12:18
11/22/19
11/22
12:18
11/22/19
12:18
General news
Ray Dalio says WSJ wrong, Bridgewater not betting market will fall »

Ray Dalio, Co-Chief…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$310.63

0.34 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/22/19
11/22
12:17
11/22/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/22/19
11/22
12:16
11/22/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$53.30

-0.425 (-0.79%)

12:15
11/22/19
11/22
12:15
11/22/19
12:15
Options
Dell Technologies put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 02

    Dec

  • 09

    Dec

  • 09

    Dec

12:15
11/22/19
11/22
12:15
11/22/19
12:15
General news
Treasury Action: the markets are mixed with no strong directional drivers »

Treasury Action: the…

RF

Regions Financial

$16.68

0.19 (1.15%)

12:05
11/22/19
11/22
12:05
11/22/19
12:05
Options
Regions Financial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

SPCE

Virgin Galactic

$7.57

-0.88 (-10.41%)

12:00
11/22/19
11/22
12:00
11/22/19
12:00
Hot Stocks
Virgin Galactic falls -10.3% »

Virgin Galactic is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PSTG

Pure Storage

$16.24

-3.6 (-18.15%)

12:00
11/22/19
11/22
12:00
11/22/19
12:00
Hot Stocks
Pure Storage falls -18.2% »

Pure Storage is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 09

    Dec

  • 12

    Dec

  • 10

    Mar

  • 11

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.